Strategic partnerships SiSaf is actively expanding through collaborations with academic institutions and industry partners (University of Leipzig, Thescientificreporters, Gala Dinner) to advance Bio-Courier miRNA programs and targeted RNA therapies, presenting opportunities for co-development, licensing, and sponsored research.

RNA delivery focus Specializing in silicon-stabilized hybrid lipid nanoparticles (sshLNP) for RNA stability and transfection efficiency, SiSaf targets rare genetic disorders and cancer, suggesting sales opportunities for enabling technologies, custom formulations, and contract research around RNA delivery.

Executive leadership Led by founder Dr Suzanne Saffie-Siebert with recent executive additions such as a Chief AI Officer and a board appointment, SiSaf demonstrates growth and governance momentum that can attract strategic investors, grant partnerships, and technology licensing discussions.

Funding and growth With venture capital backing and a clear development pipeline, SiSaf presents an opportunity to co-invest, participate in funding rounds, or structure milestone-based collaborations that align with their fast-track development capabilities.

Global collaborations Active collaborations with universities and biotech partners across Europe indicate openness to international partnerships, enabling market-entry planning, joint research ventures, and access to global networks for distribution and clinical development.